Cumberland Pharmaceuticals Inc（CPIX）の財務CPIXCumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc (CPIX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sancuso, accounting for 32.1% of total sales, equivalent to $2.93M. Other significant revenue streams include Vibativ and Talicia. Understanding this composition is critical for investors evaluating how CPIX navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Cumberland Pharmaceuticals Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1898.65%, while the net margin is -1864.84%. These profitability ratios, combined with a Return on Equity (ROE) of -14.09%, provide a clear picture of how effectively CPIX converts its operational activities into shareholder value.

In the context of the broader market, CPIX competes directly with industry leaders such as AARD and VTVT. With a market capitalization of $100.24M, it holds a significant position in the sector. When comparing efficiency, CPIX's gross margin of 100.00% stands against AARD's N/A and VTVT's N/A. Such benchmarking helps identify whether Cumberland Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

CPIX has shown fluctuating revenue with a total revenue of $13.7 million in Q4 2025, but it reported a net income loss of -3.1 million in Q2 2026. The gross margin is relatively strong at 65.14% in Q1 2026, indicating good cost management on sales.